An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (BDTX) CEO, Dr. Mark A. Velleca, to participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference. The company is focused on developing MasterKey therapies for genetically defined cancers.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA.
A live webcast of the panel can be accessed by visiting the investor relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
About Black Diamond Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.
Contacts
For Investors: Mario Corso, Head of Investor Relations, Black Diamond Therapeutics mcorso@bdtx.com
When will Dr. Mark A. Velleca participate in the panel discussion on lung cancer?
Dr. Mark A. Velleca will participate in the panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA.
What type of therapies is Black Diamond Therapeutics developing?
Black Diamond Therapeutics is developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers.
Where can the live webcast of the panel discussion be accessed?
The live webcast of the panel discussion can be accessed by visiting the investor relations section of the Company’s website at www.blackdiamondtherapeutics.com.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.